"Airway Management And The Hypoglossal Nerve Stimulator For Obstructive" by Chandler Barnes
 

Faculty Advisor(s)

Kevin Seale

Document Type

Capstone

Publication Date

5-2022

Rights

© 2022 Chandler Barnes

Abstract

The pathophysiology of obstructive sleep apnea (OSA) relates to anatomical and non-anatomical factors. Anatomical considerations correlate to narrowing of the pharynx. When present, non-anatomical factors can intensify the severity of OSA and ease of collapsibility of upper airway tissue. The negative consequences of untreated OSA are well-defined and many treatment options are available. The novel hypoglossal nerve stimulator makes for a viable treatment option in patients who do not tolerate more traditional therapy, such as continuous positive airway pressure (CPAP), and meets eligibility requirements of device implantation as outlined by the Food and Drug Administration (FDA). The Inspire® Hypoglossal Nerve Stimulator has been FDA-approved since 2014. With countless reports of OSA patients who struggle to comply with CPAP therapy, this device appears to have widespread application. As successful implementation of the Hypoglossal Nerve Stimulator (HNS) continues to grow, the anesthesia provider should be informed on how to safely provide anesthetics for patients with the hypoglossal nerve stimulator. This article discusses the pathophysiology of the obstructing nature of OSA and evaluates how airway management could differ in the future with anesthetized spontaneously breathing OSA patients that have the novel hypoglossal nerve stimulator compared to patients managed by more traditional therapies.

Comments

Master's capstone

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.